Emergent BioSolutions (EBS) Total Non-Current Liabilities (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Total Non-Current Liabilities of $755.6 million for Q1 2026, down 9.83% year-over-year from $838.0 million in Q1 2025, and up 1.82% quarter-over-quarter from $742.1 million in Q4 2025.
Emergent BioSolutions (EBS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $755.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 9.83% year-over-year to $755.6 million; the TTM figure through Mar 2026 stood at $755.6 million (down 9.83% YoY), while the FY2025 annual figure was $742.1 million, down 14.48% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $755.6 million, up from $742.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.7 billion in Q4 2022, with the low at $742.1 million in Q4 2025.
- The 5-year median for Total Non-Current Liabilities is $1.1 billion (2024), against an average of $1.1 billion.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 49.08% in 2023, then sank 35.48% in 2024.
- Emergent BioSolutions' Total Non-Current Liabilities stood at $1.7 billion in 2022, then slumped by 34.09% to $1.1 billion in 2023, then dropped by 24.21% to $867.8 million in 2024, then fell by 14.48% to $742.1 million in 2025, then climbed by 1.82% to $755.6 million in 2026.
- Business Quant data shows EBS's Total Non-Current Liabilities at $755.6 million in Q1 2026, $742.1 million in Q4 2025, and $835.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 740.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 740.00 Mn |
| Mar 31, 2026 | 755.60 Mn |
| Dec 31, 2025 | 742.10 Mn |
| Sep 30, 2025 | 835.90 Mn |
| Jun 30, 2025 | 841.40 Mn |
| Mar 31, 2025 | 838.00 Mn |
| Dec 31, 2024 | 867.80 Mn |
| Sep 30, 2024 | 933.60 Mn |
| Jun 30, 2024 | 1.10 Bn |
| Mar 31, 2024 | 1.11 Bn |
| Dec 31, 2023 | 1.15 Bn |
| Sep 30, 2023 | 1.16 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.72 Bn |
| Dec 31, 2022 | 1.74 Bn |
| Sep 30, 2022 | 1.41 Bn |
| Jun 30, 2022 | 1.16 Bn |
| Mar 31, 2022 | 1.16 Bn |
| Dec 31, 2021 | 1.28 Bn |
| Sep 30, 2021 | 1.29 Bn |